ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

IsoRay, Inc.

350 Hills Street
Suite 106
Richland, WA 99354
United States

IndustryMedical Instruments & Supplies
Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Ms. Lori A. Holmes-WoodsCEO & Director341.82kN/A1962
Mr. Michael L. KrachonVP of Sales & Marketing282.01kN/A1971
Mr. William A. Cavanagh IIIChief R&D Officer264.89kN/A1966
Mr. Jonathan R. HuntCFO & Co-Principal Financial OfficerN/AN/A1967
Ms. Jennifer StreeterInterim COO & VP of HRN/AN/A1970
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is headquartered in Richland, Washington.

Corporate Governance

IsoRay, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.